- |||||||||| Herceptin (trastuzumab) / Roche
Can some ER+/HER2+ patients be safely spared from treatment with chemotherapy plus herceptin? (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_1174; The aim is to show that ER+/HER2+ patients predicted to respond less well to ET alone using IL6ST levels, gain additional benefit from chemotherapy plus Herceptin.Patients: • Cohort A - 32 post-menopausal women (PMW) with large ER+/HER2+ BC treated with neoadjuvant (3-6 months) then adjuvant letrozole. • IL6ST levels can differentiate ER+/HER2+ BCs who respond well to ET alone and those with a poor clinical response who have a higher risk of recurrence.• NR to ET have increased expression of PI3K and MAPK pathways, consistent with active HER2 signalling.• Analysis of cohort B is underway and will elucidate the benefit in terms of recurrence-free and overall breast cancer specific survival from the addition of chemotherapy plus Herceptin to the group predicted to respond less well to ET using IL6ST.• There is potential role for IL6ST in selecting ER+/HER2+ patients that require and benefit from HER2-targeted therapies.
- |||||||||| letrozole / Generic mfg., Arimidex (anastrozole) / AstraZeneca, Remedica, Faslodex (fulvestrant) / AstraZeneca
In-depth genomic analysis of acquired resistance to multiple sequential lines of endocrine therapy in breast cancer (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_1148; Only KMT2C was identified as enriched in resistant tumours when comparing sensitive to only those that acquired resistance to 1st line LET. When comparing sensitive tumours to only those that had acquired resistance to multiple lines of ET (LET and TAM +/- AN and EX), sensitives were significantly enriched for mutations in CCDC141 and SLC9A9 and multi-drug resistant (MDR) tumours were significantly enriched for mutations in 11 genes including ESR1 and GATA3, and genes involved in cell adhesion (CDH1, FLG, FLG2 and FREM2).
- |||||||||| Ibrance (palbociclib) / Pfizer
Palbociclib in advanced male hormone positive breast cancer (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_938; Palbociclib was combined with AI+GNRH in 13 pts (50%), fulvestrant+GNRH in 4 pts (15%), letrozole alone in 3 pts (13%), and fulvestrant alone in 6 pts (23%). Palbociclib provides benefit for MBC patients with the majority of men in this study achieving clinical response to treatment.
- |||||||||| letrozole / Generic mfg.
Racial/ethnic differences in tumor infiltrating lymphocytes (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_673; We found significant % sTILs differences in ethnicity, specifically Asian (35%), Pacific Islander (38.5%) and Other (46%) category compared to White (19%) Table 1. There were no differences found in sTILs according to age, BMI or stage.
- |||||||||| Kisqali (ribociclib) / Novartis
A phase 2 randomized, double-blind, placebo-controlled study of ribociclib or placebo in combination with endocrine therapy for the treatment of premenopausal and postmenopausal Chinese women with HR+, HER2-, advanced breast cancer (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_510; Secondary endpoints are overall survival, overall response rate, clinical benefit rate, time to response, duration of response, and time to deterioration in ECOG PS. The objectives for the PK cohort are to characterize PK parameters of the RIB + LET combination, and of the RIB metabolites.
- |||||||||| letrozole / Generic mfg., Arimidex (anastrozole) / AstraZeneca, Remedica
Vaginal and sexual health of hormone-receptor positive breast cancer survivors on oral endocrine therapy: A cross-sectional study (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_427; English-speaking women with HR+ breast cancer who had a treatment history with Tamoxifen or an AI (Anastrozole, Letrozole or Exemestane) for ? Our results support the notion that side effect management and patient-provider communication should be prioritized to optimize the vaginal and sexual health of women with HR+ breast cancer receiving oral ET.Women may be unaware of potential treatment options that can help manage side effects accompanying this therapy, and possibly accept these as a new standard of life.
- |||||||||| letrozole / generics
Journal: Cloning and Characterization of wnt4a gene in a natural triploid teleost, Qi river crucian carp (Carassius auratus). (Pubmed Central) - Sep 22, 2019 In the sex-reversed testis induced by letrozole treatment, the expression level of CA-wnt4a was significantly downregulated. When CA-wnt4a expression was inhibited by injection of FH535 (an inhibitor of canonical Wnt/β-catenin signal pathway) in the ovaries, levels of cyp19a1a, foxl2 mRNA were significantly downregulated, while sox9b and cyp11c1 were upregulated, which suggested that together with Foxl2-leading estrogen pathway, CA-wnt4a signaling pathway might be involved in ovarian differentiation and repression of the male pathway gene expression in Qi river crucian carp.
- |||||||||| Ibrance (palbociclib) / Pfizer, Avastin (bevacizumab) / Roche, paclitaxel / Generic Mfg.
Serous ovarian cancer treated with palbociclib and letrozole (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_872; She received carboplatin/paclitaxel/bevacizumab combination for 8 months and stopped in view that the patient opted for a drug holiday...She was then treated with carboplatin & pegylated liposomal doxorubicin for 6 cycles...In May 2017, her CA15-3 was increasing from 55U/mL to 77U/mL, and letrozole was changed to tamoxifen...In this case, palbociclib and letrozole have shown a prolonged PFS of more than 14 months and an excellent toxicity profile. This could present a potential therapeutic role of CDK4/6 inhibition in recurrent ovarian cancers.
|